KLP Kapitalforvaltning AS Has $364,000 Stock Position in IDEAYA Biosciences, Inc. $IDYA

KLP Kapitalforvaltning AS increased its stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 16.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 17,300 shares of the company’s stock after purchasing an additional 2,400 shares during the period. KLP Kapitalforvaltning AS’s holdings in IDEAYA Biosciences were worth $364,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. boosted its stake in IDEAYA Biosciences by 180.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 2,404 shares of the company’s stock worth $39,000 after purchasing an additional 1,546 shares during the period. CWM LLC boosted its stake in IDEAYA Biosciences by 325.7% in the 1st quarter. CWM LLC now owns 2,371 shares of the company’s stock worth $39,000 after purchasing an additional 1,814 shares during the period. Signaturefd LLC boosted its stake in IDEAYA Biosciences by 374.8% in the 1st quarter. Signaturefd LLC now owns 2,877 shares of the company’s stock worth $47,000 after purchasing an additional 2,271 shares during the period. Parallel Advisors LLC boosted its stake in IDEAYA Biosciences by 72.4% in the 2nd quarter. Parallel Advisors LLC now owns 3,260 shares of the company’s stock worth $69,000 after purchasing an additional 1,369 shares during the period. Finally, Exchange Traded Concepts LLC boosted its stake in IDEAYA Biosciences by 46.4% in the 1st quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company’s stock worth $109,000 after purchasing an additional 2,112 shares during the period. 98.29% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on IDYA shares. Royal Bank Of Canada upped their target price on shares of IDEAYA Biosciences from $36.00 to $38.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 9th. Wall Street Zen cut shares of IDEAYA Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, October 11th. Barclays assumed coverage on shares of IDEAYA Biosciences in a research report on Thursday, September 4th. They set an “overweight” rating and a $40.00 price target on the stock. Citizens Jmp began coverage on shares of IDEAYA Biosciences in a research report on Thursday, September 4th. They set a “mkt outperform” rating and a $41.00 price target on the stock. Finally, Guggenheim began coverage on shares of IDEAYA Biosciences in a research note on Thursday, September 18th. They issued a “buy” rating and a $50.00 price target on the stock. Fourteen research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $43.36.

IDEAYA Biosciences Price Performance

Shares of IDEAYA Biosciences stock opened at $29.26 on Monday. IDEAYA Biosciences, Inc. has a fifty-two week low of $13.45 and a fifty-two week high of $32.67. The firm has a market capitalization of $2.56 billion, a P/E ratio of -7.72 and a beta of 0.14. The company’s 50 day moving average price is $25.67 and its two-hundred day moving average price is $22.25.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its earnings results on Tuesday, August 5th. The company reported ($0.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.03). The business had revenue of $6.00 million for the quarter, compared to analysts’ expectations of $3.48 million. During the same quarter in the prior year, the company earned ($0.68) EPS. IDEAYA Biosciences’s quarterly revenue was up NaN% on a year-over-year basis. On average, analysts expect that IDEAYA Biosciences, Inc. will post -3.07 earnings per share for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.